PMID- 33987959 OWN - NLM STAT- MEDLINE DCOM- 20211231 LR - 20211231 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 10 IP - 13 DP - 2021 Jul TI - Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study. PG - 4282-4290 LID - 10.1002/cam4.3966 [doi] AB - BACKGROUND: Apatinib is an oral anti-angiogenic drug, its efficacy and prognosis in cervical carcinoma are unclear. This study evaluates the effectiveness and prognostic factors of apatinib in the treatment of recurrent or advanced cervical carcinoma. METHODS: Patients with recurrent or advanced cervical cancer, who agreed to take apatinib, were recruited into this single-center and retrospective study, and administrated apatinib with or without combination of chemo- or radio-therapy until progressive disease (PD) or unacceptable toxicity. RESULTS: From March 2017 to February 2019, 53 patients were reviewed. Among them, 2 (3.77%) patients occurred complete response, 16 (30.19%) patients showed partial response, 27 (50.95%) patients had stable disease, and 8 (15.09%) patients had PD. The objective response rate and disease control rate (DCR) of these patients were 33.96% and 84.91%, respectively. The DCR of patients younger than 50, nonsquamous carcinoma, first-line apatinib therapy, combined radiotherapy, lesions within radiation field, surgical history, and Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 were significantly higher than other patients (p < 0.05). The median progression-free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.43-7.57) and 8.0 months (95% CI: 6.52-9.48), respectively. The univariable and multivariable analysis showed that the patients with an ECOG performance status score of 2 and further line therapy were associated with poor prognosis in both PFS and OS (PFS: HR =8.35, p = 0.000; HR =6.66, p = 0.001; OS: HR = 7.40, p = 0.000; HR = 3.24, p = 0.039), respectively. The most common adverse effects (AEs) were hand-foot syndrome (35.58%), hypertension (18.87%) and fatigue (15.09%). No grade 3 AEs and drug-related death occurred. CONCLUSION: The efficacy and prognosis of patients who are in good general condition and first-line apatinib combination therapy may be better than other patients. But further phase III clinical trials should be taken to prove this hypothesis. CI - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Yang, Hui AU - Yang H AUID- ORCID: 0000-0002-3152-1285 AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Chen, Min AU - Chen M AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Mei, Zijie AU - Mei Z AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Xie, Conghua AU - Xie C AUID- ORCID: 0000-0001-6623-9864 AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Zhou, Yunfeng AU - Zhou Y AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Qiu, Hui AU - Qiu H AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. AD - Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. LA - eng GR - 81703037/National Natural Science Foundation of China/ GR - znpy2019078/Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund/ GR - znpy2019080/Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210513 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Angiogenesis Inhibitors) RN - 0 (Antineoplastic Agents) RN - 0 (Pyridines) RN - 5S371K6132 (apatinib) SB - IM MH - Adenocarcinoma/*drug therapy/mortality/pathology MH - Analysis of Variance MH - Angiogenesis Inhibitors/administration & dosage/adverse effects MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - Carcinoma, Squamous Cell/drug therapy/mortality/pathology MH - Combined Modality Therapy/methods MH - Fatigue/chemically induced MH - Female MH - Hand-Foot Syndrome/etiology MH - Humans MH - Hypertension/chemically induced MH - Middle Aged MH - Neoplasm Recurrence, Local/*drug therapy/mortality MH - Prognosis MH - Progression-Free Survival MH - Pyridines/*administration & dosage/adverse effects MH - Treatment Outcome MH - Uterine Cervical Neoplasms/*drug therapy/mortality/pathology PMC - PMC8267132 OTO - NOTNLM OT - angiogenesis OT - apatinib OT - cervical carcinoma OT - efficacy OT - prognosis OT - retrospective study COIS- The authors declare no competing financial interest. EDAT- 2021/05/15 06:00 MHDA- 2022/01/01 06:00 PMCR- 2021/05/13 CRDT- 2021/05/14 07:21 PHST- 2021/03/27 00:00 [revised] PHST- 2020/08/10 00:00 [received] PHST- 2021/04/14 00:00 [accepted] PHST- 2021/05/15 06:00 [pubmed] PHST- 2022/01/01 06:00 [medline] PHST- 2021/05/14 07:21 [entrez] PHST- 2021/05/13 00:00 [pmc-release] AID - CAM43966 [pii] AID - 10.1002/cam4.3966 [doi] PST - ppublish SO - Cancer Med. 2021 Jul;10(13):4282-4290. doi: 10.1002/cam4.3966. Epub 2021 May 13.